Structured Review

Affibody taq polymerase binding
PET images, summed 30–60 min, and TACs from a Balbc nu/nu mouse (prone) bearing tumors ( white arrows ): a one A431 xenograft (1 × 10 7 cells, 15 days) or b two A431 xenografts ( left : 1 × 10 7 cells, 28 days; right : 1 × 10 7 cells, 25 days). Comparison A shows a 7-times higher uptake with targeting [methyl- 11 C]-Z <t>EGFR:2377</t> -ST-CH 3 compared to the non-targeting [methyl- 11 C]-Z <t>Taq:3638</t> -ST-CH 3 . Comparison B illustrates uptake of the targeting Affibody increasing as the tumors grow from time from inoculation
Taq Polymerase Binding, supplied by Affibody, used in various techniques. Bioz Stars score: 78/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/taq polymerase binding/product/Affibody
Average 78 stars, based on 1 article reviews
Price from $9.99 to $1999.99
taq polymerase binding - by Bioz Stars, 2020-01
78/100 stars

Images

1) Product Images from "Preclinical PET imaging of EGFR levels: pairing a targeting with a non-targeting Sel-tagged Affibody-based tracer to estimate the specific uptake"

Article Title: Preclinical PET imaging of EGFR levels: pairing a targeting with a non-targeting Sel-tagged Affibody-based tracer to estimate the specific uptake

Journal: EJNMMI Research

doi: 10.1186/s13550-016-0213-8

PET images, summed 30–60 min, and TACs from a Balbc nu/nu mouse (prone) bearing tumors ( white arrows ): a one A431 xenograft (1 × 10 7 cells, 15 days) or b two A431 xenografts ( left : 1 × 10 7 cells, 28 days; right : 1 × 10 7 cells, 25 days). Comparison A shows a 7-times higher uptake with targeting [methyl- 11 C]-Z EGFR:2377 -ST-CH 3 compared to the non-targeting [methyl- 11 C]-Z Taq:3638 -ST-CH 3 . Comparison B illustrates uptake of the targeting Affibody increasing as the tumors grow from time from inoculation
Figure Legend Snippet: PET images, summed 30–60 min, and TACs from a Balbc nu/nu mouse (prone) bearing tumors ( white arrows ): a one A431 xenograft (1 × 10 7 cells, 15 days) or b two A431 xenografts ( left : 1 × 10 7 cells, 28 days; right : 1 × 10 7 cells, 25 days). Comparison A shows a 7-times higher uptake with targeting [methyl- 11 C]-Z EGFR:2377 -ST-CH 3 compared to the non-targeting [methyl- 11 C]-Z Taq:3638 -ST-CH 3 . Comparison B illustrates uptake of the targeting Affibody increasing as the tumors grow from time from inoculation

Techniques Used: Positron Emission Tomography

Data from the longitudinal study of A431 xenografts: a Changes in tumor volumes with the days since inoculation. b TACs of the differing uptakes in one A431 xenograft of [methyl- 11 C]-Z Taq:3638 -ST-CH 3 ( black curve, day 8) and targeting [methyl- 11 C]-Z EGFR:2377 -ST-CH 3 ( red , blue , and green curves on days 8, 19, and 21, respectively). c SUV mean for the uptake of [methyl- 11 C]-Z Taq:3638 -ST-CH 3 measured in the A431 tumors vs. days since inoculation. d Variations in specific uptake (SUV mean(ZEGFR:2377) –SUV mean(ZTaq:3638) ) with the growth of all ten xenografts from inoculation. e Variations in specific uptake (SUV mean of Z EGFR:2377 –SUV mean of Z Taq:3638 ) of all ten xenografts as their volumes increased. f Variations in specific uptake, SUV mean , in individual xenografts as their volumes increased
Figure Legend Snippet: Data from the longitudinal study of A431 xenografts: a Changes in tumor volumes with the days since inoculation. b TACs of the differing uptakes in one A431 xenograft of [methyl- 11 C]-Z Taq:3638 -ST-CH 3 ( black curve, day 8) and targeting [methyl- 11 C]-Z EGFR:2377 -ST-CH 3 ( red , blue , and green curves on days 8, 19, and 21, respectively). c SUV mean for the uptake of [methyl- 11 C]-Z Taq:3638 -ST-CH 3 measured in the A431 tumors vs. days since inoculation. d Variations in specific uptake (SUV mean(ZEGFR:2377) –SUV mean(ZTaq:3638) ) with the growth of all ten xenografts from inoculation. e Variations in specific uptake (SUV mean of Z EGFR:2377 –SUV mean of Z Taq:3638 ) of all ten xenografts as their volumes increased. f Variations in specific uptake, SUV mean , in individual xenografts as their volumes increased

Techniques Used:

a Cell-binding assay of non-blocked ( red ) and blocked ( blue , tenfold Z EGFR:2377 ) Z EGFR:2377 -ST-[DyLight 488] and controls Z Taq:3638 -ST-[DyLight 488] ( green ) and DyLight 488 dye ( black ) using FACS analysis in A431 ( left ), FaDu ( middle ), and MDA-MB-453 ( right ) cells with high, medium, and low/no expressions of EGFR, respectively. b Fluorescent microscopy images of tumor (A431), liver, and kidney. Fluorescence in the tumor is only observed with the Z EGFR:2377 probe. High autofluorescence of the liver is observed with all probes. Fluorescence from both the Z EGFR:2377 and Z Taq:3638 probes is observed in the kidney. c western blots of A431, FaDu, and MDA from cell ( left ) and tumor ( right ) lysates using an antibody against human EGFR. The protein concentration of the cell lysates was determined by Bradford protein assay and Ponceau S staining of the membranes was used as loading control. The arrow indicates full-length EGFR
Figure Legend Snippet: a Cell-binding assay of non-blocked ( red ) and blocked ( blue , tenfold Z EGFR:2377 ) Z EGFR:2377 -ST-[DyLight 488] and controls Z Taq:3638 -ST-[DyLight 488] ( green ) and DyLight 488 dye ( black ) using FACS analysis in A431 ( left ), FaDu ( middle ), and MDA-MB-453 ( right ) cells with high, medium, and low/no expressions of EGFR, respectively. b Fluorescent microscopy images of tumor (A431), liver, and kidney. Fluorescence in the tumor is only observed with the Z EGFR:2377 probe. High autofluorescence of the liver is observed with all probes. Fluorescence from both the Z EGFR:2377 and Z Taq:3638 probes is observed in the kidney. c western blots of A431, FaDu, and MDA from cell ( left ) and tumor ( right ) lysates using an antibody against human EGFR. The protein concentration of the cell lysates was determined by Bradford protein assay and Ponceau S staining of the membranes was used as loading control. The arrow indicates full-length EGFR

Techniques Used: Cell Binding Assay, FACS, Multiple Displacement Amplification, Microscopy, Fluorescence, Western Blot, Protein Concentration, Bradford Protein Assay, Staining

Biodistribution of [methyl- 11 C]-Z EGFR:2377 -ST-CH 3 and [methyl- 11 C]-Z Taq:3638 -ST-CH 3 in healthy Balb/c mice ( black lines Z EGFR:2377 and blue lines Z Taq:3638 (means ± SD, n = 4 mice): a PET images (supine, summed from 30–60 min, 3-D volume rendering) and b time activity curves (SUV) in arterial and venous blood, skeletal muscle, liver, and kidney over 60 min after injection
Figure Legend Snippet: Biodistribution of [methyl- 11 C]-Z EGFR:2377 -ST-CH 3 and [methyl- 11 C]-Z Taq:3638 -ST-CH 3 in healthy Balb/c mice ( black lines Z EGFR:2377 and blue lines Z Taq:3638 (means ± SD, n = 4 mice): a PET images (supine, summed from 30–60 min, 3-D volume rendering) and b time activity curves (SUV) in arterial and venous blood, skeletal muscle, liver, and kidney over 60 min after injection

Techniques Used: Mouse Assay, Positron Emission Tomography, Activity Assay, Injection

PET images, summed 30–60 min, and TACs from a SCID mouse (prone) bearing tumors ( white arrows ): a one FaDu xenograft (1 × 10 6 cells, 12 days) or b two FaDu xenografts ( left : (1 × 10 6 cells, 12 days); right : (0.5 × 10 6 cells, 12 days). Comparison A illustrates the higher uptake with targeting [methyl- 11 C]-Z EGFR:2377 -ST-CH 3 but with a ≈60 % non-targeting uptake of [methyl- 11 C]-Z Taq:3638 -ST-CH 3 . Comparison B illustrates the visually discernable heterogeneous uptake of the targeting Affibody in the larger tumor on the left. SUV mean is affected by whether the entire (1) or only central ROI (2) of the left tumor is used
Figure Legend Snippet: PET images, summed 30–60 min, and TACs from a SCID mouse (prone) bearing tumors ( white arrows ): a one FaDu xenograft (1 × 10 6 cells, 12 days) or b two FaDu xenografts ( left : (1 × 10 6 cells, 12 days); right : (0.5 × 10 6 cells, 12 days). Comparison A illustrates the higher uptake with targeting [methyl- 11 C]-Z EGFR:2377 -ST-CH 3 but with a ≈60 % non-targeting uptake of [methyl- 11 C]-Z Taq:3638 -ST-CH 3 . Comparison B illustrates the visually discernable heterogeneous uptake of the targeting Affibody in the larger tumor on the left. SUV mean is affected by whether the entire (1) or only central ROI (2) of the left tumor is used

Techniques Used: Positron Emission Tomography

Related Articles

Negative Control:

Article Title: Cellular Effects of HER3-Specific Affibody Molecules
Article Snippet: The Affibody molecules were produced in E. coli and purified by IMAC as previously described . .. As a negative control, a Taq-polymerase binding Affibody, His-Z01155-Cys, was used (here referred to as ZTaq). .. Since Taq polymerase is not naturally occurring in cells, ZTaq is not supposed to bind to or affect cells.

Purification:

Article Title: Preclinical PET imaging of EGFR levels: pairing a targeting with a non-targeting Sel-tagged Affibody-based tracer to estimate the specific uptake
Article Snippet: The EGFR-binding Affibody molecule ZEGFR:2377 [ , ] and the irrelevant Taq polymerase-binding Affibody molecule ZTaq:3638 [ ] were fused with a C-terminal ST as previously described [ , ]. .. Gene expression was induced by adding isopropyl β-D-1-thiogalactopyranoside to a final concentration of 0.5 mM. l -Cysteine and selenite were added to the cultures to a final concentration of 1 μM and 5 nM, respectively, and cultivations were continued overnight at 25 °C.

Article Title: Cellular Effects of HER3-Specific Affibody Molecules
Article Snippet: The Affibody molecules were produced in E. coli and purified by IMAC as previously described . .. As a negative control, a Taq-polymerase binding Affibody, His-Z01155-Cys, was used (here referred to as ZTaq).

Produced:

Article Title: Cellular Effects of HER3-Specific Affibody Molecules
Article Snippet: The Affibody molecules were produced in E. coli and purified by IMAC as previously described . .. As a negative control, a Taq-polymerase binding Affibody, His-Z01155-Cys, was used (here referred to as ZTaq).

Concentration Assay:

Article Title: Preclinical PET imaging of EGFR levels: pairing a targeting with a non-targeting Sel-tagged Affibody-based tracer to estimate the specific uptake
Article Snippet: The EGFR-binding Affibody molecule ZEGFR:2377 [ , ] and the irrelevant Taq polymerase-binding Affibody molecule ZTaq:3638 [ ] were fused with a C-terminal ST as previously described [ , ]. .. The EGFR-binding Affibody molecule ZEGFR:2377 [ , ] and the irrelevant Taq polymerase-binding Affibody molecule ZTaq:3638 [ ] were fused with a C-terminal ST as previously described [ , ].

Expressing:

Article Title: Preclinical PET imaging of EGFR levels: pairing a targeting with a non-targeting Sel-tagged Affibody-based tracer to estimate the specific uptake
Article Snippet: Paragraph title: DNA constructions and expression of Sel-tagged Affibody molecules ... The EGFR-binding Affibody molecule ZEGFR:2377 [ , ] and the irrelevant Taq polymerase-binding Affibody molecule ZTaq:3638 [ ] were fused with a C-terminal ST as previously described [ , ].

Binding Assay:

Article Title: Cellular Effects of HER3-Specific Affibody Molecules
Article Snippet: The Affibody molecules were produced in E. coli and purified by IMAC as previously described . .. As a negative control, a Taq-polymerase binding Affibody, His-Z01155-Cys, was used (here referred to as ZTaq). .. Since Taq polymerase is not naturally occurring in cells, ZTaq is not supposed to bind to or affect cells.

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 78
    Affibody taq polymerase binding
    PET images, summed 30–60 min, and TACs from a Balbc nu/nu mouse (prone) bearing tumors ( white arrows ): a one A431 xenograft (1 × 10 7 cells, 15 days) or b two A431 xenografts ( left : 1 × 10 7 cells, 28 days; right : 1 × 10 7 cells, 25 days). Comparison A shows a 7-times higher uptake with targeting [methyl- 11 C]-Z <t>EGFR:2377</t> -ST-CH 3 compared to the non-targeting [methyl- 11 C]-Z <t>Taq:3638</t> -ST-CH 3 . Comparison B illustrates uptake of the targeting Affibody increasing as the tumors grow from time from inoculation
    Taq Polymerase Binding, supplied by Affibody, used in various techniques. Bioz Stars score: 78/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/taq polymerase binding/product/Affibody
    Average 78 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    taq polymerase binding - by Bioz Stars, 2020-01
    78/100 stars
      Buy from Supplier

    Image Search Results


    PET images, summed 30–60 min, and TACs from a Balbc nu/nu mouse (prone) bearing tumors ( white arrows ): a one A431 xenograft (1 × 10 7 cells, 15 days) or b two A431 xenografts ( left : 1 × 10 7 cells, 28 days; right : 1 × 10 7 cells, 25 days). Comparison A shows a 7-times higher uptake with targeting [methyl- 11 C]-Z EGFR:2377 -ST-CH 3 compared to the non-targeting [methyl- 11 C]-Z Taq:3638 -ST-CH 3 . Comparison B illustrates uptake of the targeting Affibody increasing as the tumors grow from time from inoculation

    Journal: EJNMMI Research

    Article Title: Preclinical PET imaging of EGFR levels: pairing a targeting with a non-targeting Sel-tagged Affibody-based tracer to estimate the specific uptake

    doi: 10.1186/s13550-016-0213-8

    Figure Lengend Snippet: PET images, summed 30–60 min, and TACs from a Balbc nu/nu mouse (prone) bearing tumors ( white arrows ): a one A431 xenograft (1 × 10 7 cells, 15 days) or b two A431 xenografts ( left : 1 × 10 7 cells, 28 days; right : 1 × 10 7 cells, 25 days). Comparison A shows a 7-times higher uptake with targeting [methyl- 11 C]-Z EGFR:2377 -ST-CH 3 compared to the non-targeting [methyl- 11 C]-Z Taq:3638 -ST-CH 3 . Comparison B illustrates uptake of the targeting Affibody increasing as the tumors grow from time from inoculation

    Article Snippet: The EGFR-binding Affibody molecule ZEGFR:2377 [ , ] and the irrelevant Taq polymerase-binding Affibody molecule ZTaq:3638 [ ] were fused with a C-terminal ST as previously described [ , ].

    Techniques: Positron Emission Tomography

    Data from the longitudinal study of A431 xenografts: a Changes in tumor volumes with the days since inoculation. b TACs of the differing uptakes in one A431 xenograft of [methyl- 11 C]-Z Taq:3638 -ST-CH 3 ( black curve, day 8) and targeting [methyl- 11 C]-Z EGFR:2377 -ST-CH 3 ( red , blue , and green curves on days 8, 19, and 21, respectively). c SUV mean for the uptake of [methyl- 11 C]-Z Taq:3638 -ST-CH 3 measured in the A431 tumors vs. days since inoculation. d Variations in specific uptake (SUV mean(ZEGFR:2377) –SUV mean(ZTaq:3638) ) with the growth of all ten xenografts from inoculation. e Variations in specific uptake (SUV mean of Z EGFR:2377 –SUV mean of Z Taq:3638 ) of all ten xenografts as their volumes increased. f Variations in specific uptake, SUV mean , in individual xenografts as their volumes increased

    Journal: EJNMMI Research

    Article Title: Preclinical PET imaging of EGFR levels: pairing a targeting with a non-targeting Sel-tagged Affibody-based tracer to estimate the specific uptake

    doi: 10.1186/s13550-016-0213-8

    Figure Lengend Snippet: Data from the longitudinal study of A431 xenografts: a Changes in tumor volumes with the days since inoculation. b TACs of the differing uptakes in one A431 xenograft of [methyl- 11 C]-Z Taq:3638 -ST-CH 3 ( black curve, day 8) and targeting [methyl- 11 C]-Z EGFR:2377 -ST-CH 3 ( red , blue , and green curves on days 8, 19, and 21, respectively). c SUV mean for the uptake of [methyl- 11 C]-Z Taq:3638 -ST-CH 3 measured in the A431 tumors vs. days since inoculation. d Variations in specific uptake (SUV mean(ZEGFR:2377) –SUV mean(ZTaq:3638) ) with the growth of all ten xenografts from inoculation. e Variations in specific uptake (SUV mean of Z EGFR:2377 –SUV mean of Z Taq:3638 ) of all ten xenografts as their volumes increased. f Variations in specific uptake, SUV mean , in individual xenografts as their volumes increased

    Article Snippet: The EGFR-binding Affibody molecule ZEGFR:2377 [ , ] and the irrelevant Taq polymerase-binding Affibody molecule ZTaq:3638 [ ] were fused with a C-terminal ST as previously described [ , ].

    Techniques:

    a Cell-binding assay of non-blocked ( red ) and blocked ( blue , tenfold Z EGFR:2377 ) Z EGFR:2377 -ST-[DyLight 488] and controls Z Taq:3638 -ST-[DyLight 488] ( green ) and DyLight 488 dye ( black ) using FACS analysis in A431 ( left ), FaDu ( middle ), and MDA-MB-453 ( right ) cells with high, medium, and low/no expressions of EGFR, respectively. b Fluorescent microscopy images of tumor (A431), liver, and kidney. Fluorescence in the tumor is only observed with the Z EGFR:2377 probe. High autofluorescence of the liver is observed with all probes. Fluorescence from both the Z EGFR:2377 and Z Taq:3638 probes is observed in the kidney. c western blots of A431, FaDu, and MDA from cell ( left ) and tumor ( right ) lysates using an antibody against human EGFR. The protein concentration of the cell lysates was determined by Bradford protein assay and Ponceau S staining of the membranes was used as loading control. The arrow indicates full-length EGFR

    Journal: EJNMMI Research

    Article Title: Preclinical PET imaging of EGFR levels: pairing a targeting with a non-targeting Sel-tagged Affibody-based tracer to estimate the specific uptake

    doi: 10.1186/s13550-016-0213-8

    Figure Lengend Snippet: a Cell-binding assay of non-blocked ( red ) and blocked ( blue , tenfold Z EGFR:2377 ) Z EGFR:2377 -ST-[DyLight 488] and controls Z Taq:3638 -ST-[DyLight 488] ( green ) and DyLight 488 dye ( black ) using FACS analysis in A431 ( left ), FaDu ( middle ), and MDA-MB-453 ( right ) cells with high, medium, and low/no expressions of EGFR, respectively. b Fluorescent microscopy images of tumor (A431), liver, and kidney. Fluorescence in the tumor is only observed with the Z EGFR:2377 probe. High autofluorescence of the liver is observed with all probes. Fluorescence from both the Z EGFR:2377 and Z Taq:3638 probes is observed in the kidney. c western blots of A431, FaDu, and MDA from cell ( left ) and tumor ( right ) lysates using an antibody against human EGFR. The protein concentration of the cell lysates was determined by Bradford protein assay and Ponceau S staining of the membranes was used as loading control. The arrow indicates full-length EGFR

    Article Snippet: The EGFR-binding Affibody molecule ZEGFR:2377 [ , ] and the irrelevant Taq polymerase-binding Affibody molecule ZTaq:3638 [ ] were fused with a C-terminal ST as previously described [ , ].

    Techniques: Cell Binding Assay, FACS, Multiple Displacement Amplification, Microscopy, Fluorescence, Western Blot, Protein Concentration, Bradford Protein Assay, Staining

    Biodistribution of [methyl- 11 C]-Z EGFR:2377 -ST-CH 3 and [methyl- 11 C]-Z Taq:3638 -ST-CH 3 in healthy Balb/c mice ( black lines Z EGFR:2377 and blue lines Z Taq:3638 (means ± SD, n = 4 mice): a PET images (supine, summed from 30–60 min, 3-D volume rendering) and b time activity curves (SUV) in arterial and venous blood, skeletal muscle, liver, and kidney over 60 min after injection

    Journal: EJNMMI Research

    Article Title: Preclinical PET imaging of EGFR levels: pairing a targeting with a non-targeting Sel-tagged Affibody-based tracer to estimate the specific uptake

    doi: 10.1186/s13550-016-0213-8

    Figure Lengend Snippet: Biodistribution of [methyl- 11 C]-Z EGFR:2377 -ST-CH 3 and [methyl- 11 C]-Z Taq:3638 -ST-CH 3 in healthy Balb/c mice ( black lines Z EGFR:2377 and blue lines Z Taq:3638 (means ± SD, n = 4 mice): a PET images (supine, summed from 30–60 min, 3-D volume rendering) and b time activity curves (SUV) in arterial and venous blood, skeletal muscle, liver, and kidney over 60 min after injection

    Article Snippet: The EGFR-binding Affibody molecule ZEGFR:2377 [ , ] and the irrelevant Taq polymerase-binding Affibody molecule ZTaq:3638 [ ] were fused with a C-terminal ST as previously described [ , ].

    Techniques: Mouse Assay, Positron Emission Tomography, Activity Assay, Injection

    PET images, summed 30–60 min, and TACs from a SCID mouse (prone) bearing tumors ( white arrows ): a one FaDu xenograft (1 × 10 6 cells, 12 days) or b two FaDu xenografts ( left : (1 × 10 6 cells, 12 days); right : (0.5 × 10 6 cells, 12 days). Comparison A illustrates the higher uptake with targeting [methyl- 11 C]-Z EGFR:2377 -ST-CH 3 but with a ≈60 % non-targeting uptake of [methyl- 11 C]-Z Taq:3638 -ST-CH 3 . Comparison B illustrates the visually discernable heterogeneous uptake of the targeting Affibody in the larger tumor on the left. SUV mean is affected by whether the entire (1) or only central ROI (2) of the left tumor is used

    Journal: EJNMMI Research

    Article Title: Preclinical PET imaging of EGFR levels: pairing a targeting with a non-targeting Sel-tagged Affibody-based tracer to estimate the specific uptake

    doi: 10.1186/s13550-016-0213-8

    Figure Lengend Snippet: PET images, summed 30–60 min, and TACs from a SCID mouse (prone) bearing tumors ( white arrows ): a one FaDu xenograft (1 × 10 6 cells, 12 days) or b two FaDu xenografts ( left : (1 × 10 6 cells, 12 days); right : (0.5 × 10 6 cells, 12 days). Comparison A illustrates the higher uptake with targeting [methyl- 11 C]-Z EGFR:2377 -ST-CH 3 but with a ≈60 % non-targeting uptake of [methyl- 11 C]-Z Taq:3638 -ST-CH 3 . Comparison B illustrates the visually discernable heterogeneous uptake of the targeting Affibody in the larger tumor on the left. SUV mean is affected by whether the entire (1) or only central ROI (2) of the left tumor is used

    Article Snippet: The EGFR-binding Affibody molecule ZEGFR:2377 [ , ] and the irrelevant Taq polymerase-binding Affibody molecule ZTaq:3638 [ ] were fused with a C-terminal ST as previously described [ , ].

    Techniques: Positron Emission Tomography